Last updated: 23 June 2022 at 4:35pm EST

Jay Lichter Net Worth




The estimated Net Worth of Jay Lichter is at least $22.4 Million dollars as of 26 February 2021. Jay Lichter owns over 893,828 units of Otonomy Inc stock worth over $8,773 and over the last 11 years he sold OTIC stock worth over $22,300,414. In addition, he makes $91,511 as Independent Chairman of the Board at Otonomy Inc.

Jay Lichter OTIC stock SEC Form 4 insiders trading

Jay has made over 7 trades of the Otonomy Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 321,180 units of OTIC stock worth $867,186 on 3 March 2021.

The largest trade he's ever made was selling 1,082,353 units of Otonomy Inc stock on 23 February 2021 worth over $3,192,941. On average, Jay trades about 170,359 units every 112 days since 2013. As of 26 February 2021 he still owns at least 113,935 units of Otonomy Inc stock.

You can see the complete history of Jay Lichter stock trades at the bottom of the page.





Jay Lichter biography

Dr. Jay B. Lichter Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Lichter served as our Chief Executive Officer from inception until November 2010. Dr. Lichter is currently chief executive officer of Avelas BioSciences and Fortis, both private biotechnology companies. He is an experienced biotechnology and pharmaceutical business executive with over 25 years of experience in management, scientific research and business development. Since 2007, Dr. Lichter has been a managing director at Avalon Ventures, an early-stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon’s investments in public companies SynthoRx, Inc. and Aratana Therepeutics, Inc., and served as a director and chief executive officer for several privately-held biotechnology companies. He previously served on the board of directors of Aratana Therapeutics, Inc., a public pharmaceutical company, from December 2010 to August 2015, and currently serves on the board of directors of SynthoRx, Inc., a biotechnology company. Dr. Lichter also led Avalon’s investments in or currently serves on the board of several privately-held companies, including AristaMD, Fortis Therapeutics, Inc., Avelas BioSciences, Inc., COI Pharmaceuticals Inc., Sitari Pharmaceuticals Corp. and Sova Pharmaceuticals, Inc., among other life science companies. Dr. Lichter received a Bachelor’s degree and Ph.D. in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.

What is the salary of Jay Lichter?

As the Independent Chairman of the Board of Otonomy Inc, the total compensation of Jay Lichter at Otonomy Inc is $91,511. There are 6 executives at Otonomy Inc getting paid more, with David Weber having the highest compensation of $2,153,120.



How old is Jay Lichter?

Jay Lichter is 58, he's been the Independent Chairman of the Board of Otonomy Inc since 2015. There are 7 older and 4 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.

What's Jay Lichter's mailing address?

Jay's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Otonomy Inc

Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo, and Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.



What does Otonomy Inc do?

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.



Complete history of Jay Lichter stock trades at Otonomy Inc

Insider
Trans.
Transaction
Total value
Jay Lichter
Director
Sale $867,186
3 Mar 2021
Jay Lichter
Director
Sale $2,565,286
26 Feb 2021
Jay Lichter
Director
Sale $3,192,941
23 Feb 2021
Jay Lichter
Director
Option $2,000,231
31 Aug 2017
Jay Lichter
Director
Buy $1,750,000
18 Aug 2014


Otonomy Inc executives and stock owners

Otonomy Inc executives and other stock owners filed with the SEC include: